CorVel (CRVL) AI Stock Analysis

• Market Cap: $3.87B
• Dividend Yield: N/A
• Average Volume (3M): 157.50K
• Price to Earnings (P/E): 37.1
• Beta (1Y): 0.77
• Revenue Growth: 10.43%
• EPS Growth: 29.22%
• Country: US
• Employees: 4,870
• Sector: Financial
• Sector Strength: 70
• Industry: Insurance - Brokers
• EPS (TTM): 0.54
• Shares Outstanding: 51,312,748
• 10 Day Avg. Volume: 163,628
• 30 Day Avg. Volume: 157,505
• PEG Ratio: 2.42
• Price to Book (P/B): 17.87
• Price to Sales (P/S): 6.42
• P/FCF Ratio: 62.84
• Enterprise Value/Market Cap: 0.99
• Enterprise Value/Revenue: 4.09
• Enterprise Value/Gross Profit: 22.86
• Enterprise Value/Ebitda: 31.61
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 60 Neutral
• Price Target: $77.00 ▲(4.28% Upside)

CorVel's strong financial performance is a key strength, supported by consistent growth and solid financial management. However, bearish technical indicators and a high valuation relative to earnings limit the stock's attractiveness. The absence of earnings call insights and corporate events further emphasizes reliance on existing financial and technical data.

CorVel Business Overview & Revenue Model

Company Description

CorVel Corporation provides workers' compensation, auto, liability, and health solutions for employers, third party administrators, insurance companies, and government agencies to assist them in managing the medical costs and monitoring the quality of care associated with healthcare claims. It applies technology, including artificial intelligence, machine learning, and natural language processing to enhance the managing of episodes of care and the related health care costs. The company offers network solutions services, including automated medical fee auditing, preferred provider management and reimbursement services, retrospective utilization review, facility claim review, professional review, pharmacy services, directed care services, Medicare solutions, clearinghouse services, independent medical examinations, and inpatient medical bill review. It also provides a range of patient management services, such as claims management, case management, 24/7 nurse triage, utilization management, vocational rehabilitation, and life care planning, as well as processing of claims for self-insured payors with respect to property and casualty insurance. The company was incorporated in 1987 and is headquartered in Fort Worth, Texas.

How the Company Makes Money

CorVel generates revenue through a diversified model that includes fees for its various services. Key revenue streams comprise the management of workers' compensation claims, which includes medical and non-medical cost containment services, and the provision of pharmacy benefit management services. The company also earns income from its advanced data analytics and technology solutions that assist clients in making informed decisions regarding risk management. Significant partnerships with insurance companies, third-party administrators, and self-insured employers enhance CorVel's ability to capture a larger market share and drive revenue growth. Additionally, the company benefits from economies of scale as it expands its client base, allowing it to optimize operational efficiencies and increase profitability.

CorVel Financial Statement Overview

Summary

CorVel exhibits strong financial health with consistent revenue and profit growth, solid margins, and efficient cash flow management. The company's conservative leverage enhances financial stability, positioning it well for future growth.

Income Statement

CorVel has demonstrated consistent revenue growth, with a TTM revenue growth rate of 2.57%. The company maintains strong profitability metrics, including a gross profit margin of 23.77% and a net profit margin of 10.98%. EBIT and EBITDA margins are also healthy at 13.94% and 16.43%, respectively. These figures indicate a stable and profitable operation, with a positive growth trajectory.

Balance Sheet

The balance sheet reflects a solid financial position with a low debt-to-equity ratio of 0.06, indicating prudent financial leverage. The return on equity is impressive at 32.31%, showcasing effective utilization of shareholder funds. An equity ratio of 57.34% suggests a strong equity base relative to total assets, contributing to financial stability.

Cash Flow

CorVel's cash flow performance is robust, with a free cash flow growth rate of 7.41% in the TTM period. The operating cash flow to net income ratio stands at 1.41, indicating efficient cash generation relative to net income. The free cash flow to net income ratio of 0.72 further underscores the company's ability to convert earnings into cash, supporting ongoing operations and potential investments.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	933.84M	895.59M	795.31M	718.56M	646.23M	552.64M
Gross Profit	166.92M	209.73M	171.69M	158.26M	152.11M	123.62M
EBITDA	120.69M	150.36M	121.35M	109.67M	108.43M	82.61M
Net Income	78.51M	95.17M	76.25M	66.36M	66.41M	46.36M
Balance Sheet
Total Assets	611.68M	545.98M	454.68M	393.92M	415.25M	424.76M
Cash, Cash Equivalents and Short-Term Investments	207.45M	170.58M	105.56M	71.33M	97.50M	139.72M
Total Debt	18.57M	28.08M	31.40M	33.76M	43.14M	54.66M
Total Liabilities	248.90M	223.99M	207.03M	191.75M	202.85M	204.36M
Stockholders Equity	362.78M	321.99M	247.65M	202.18M	212.40M	220.40M
Cash Flow
Free Cash Flow	101.19M	91.56M	70.00M	55.97M	37.40M	77.14M
Operating Cash Flow	144.60M	127.31M	99.24M	82.29M	67.22M	94.38M
Investing Cash Flow	-43.41M	-35.76M	-29.24M	-26.32M	-29.82M	-17.24M
Financing Cash Flow	-32.09M	-26.54M	-35.76M	-82.14M	-79.61M	-20.64M

CorVel Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 73.84
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRVL, the sentiment is Neutral. The current price of 73.84 is below the 20-day moving average (MA) of 74.02, below the 50-day MA of 78.01, and below the 200-day MA of 98.87, indicating a neutral trend. The MACD of -0.54 indicates Negative momentum. The RSI at 52.00 is Neutral, neither overbought nor oversold. The STOCH value of 50.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CRVL.

CorVel Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BRO	71 Outperform	$26.58B	23.36	10.47%	0.78%	17.87%	-9.35%
CRD.A	71 Outperform	$525.01M	16.90	18.72%	2.62%	4.39%	61.61%
Sector *	68 Neutral	$18.00B	11.42	9.92%	3.81%	9.73%	1.22%
CRD.B	67 Neutral	$525.01M	15.48	18.72%	2.84%	4.39%	61.61%
TWFG	67 Neutral	$1.37B	60.20	8.26%	―	17.86%	-77.16%
CRVL	60 Neutral	$3.87B	37.13	32.63%	―	10.43%	29.22%
BWIN	49 Neutral	$2.73B	-80.03	-4.63%	―	10.69%	32.74%

CorVel Corporate Events

CorVel Holds 2025 Annual Stockholders Meeting

On August 7, 2025, CorVel Corporation held its 2025 Annual Meeting of Stockholders, where shareholders voted on three key proposals. The election of six directors to serve until the 2026 meeting was conducted, with varying levels of support for each candidate. Additionally, the appointment of Haskell & White LLP as the independent registered public accounting firm for the fiscal year ending March 31, 2026, was ratified. Lastly, the 2025 Stock Incentive Plan was approved, indicating continued strategic focus on incentivizing performance and aligning interests with shareholders.

CorVel Reports Strong Quarterly Earnings Growth

CorVel Corporation is a healthcare management company specializing in providing technology-driven solutions for workers’ compensation, auto, and liability claims management.